External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home ISTH 2025
Roche and Genentech at

ISTH 2025

June 21 - June 25
Washington, USA / Virtual (Hybrid)
isth2025.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
01:45 PM
Duration 15mins Walter E. Washington Convention Center
Plasma proteomics and collagen biomarkers in people with hemophilia A receiving emicizumab in STASEY
Kiialainen A, Nowicka M, Bay-Jensen A-C, Karsdal MA, Ozelo MC, Jiménez-Yuste V, Locke M, Ling G, Klamroth R, Castaman G
Haematology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 15mins Walter E. Washington Convention Center
Factor VIII inhibitor titers in people with hemophilia A on emicizumab prophylaxis in ATHN 7
Chrisentery-Singleton T, Daoud N, Lee L, Gao L, O'Neill CE, Schwartz J, Recht M
Haematology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:45 PM
Duration 60mins Washington, USA
Method comparison study of activated partial thromboplastin time reagents
Rodríguez-Enfedaque A, Bernhardt B, Zimmermann L, Ambròs R, Jagdhuber F
Haematology | Blood coagulation disorder

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:45 PM
Duration 60mins Washington, USA
The impact of emicizumab on averted bleeds and hospitalization days in people with hemophilia A
Arnold M, Kagkelari Y, Crasaris A, Veržun P, Ajjouri R, Al-Adwan M
Haematology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Washington, USA
Hemoglobin increase in children with hemophilia A on emicizumab: HAVEN 2 & 7 post hoc analysis
Batsuli G, Tzeng E, Gao L, Lim E, Sidonio R
Haematology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Washington, USA
Factor VIII activity in people with mild hemophilia A receiving emicizumab in the HAVEN 6 trial
Shapiro AD, Tzeng E, Lim E, Hermans C
Haematology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Washington, USA
SPK-8011 vector genome maintains an active transcriptional state for up to 72 weeks in adult mice
Lupo D, Rizzo C, Elliott S, Blanchard EL, Peterson D, Rivera-Pena G, Li C, Atkins G, Nowrouzi A, Alexander JM, Hanby H
Haematology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:45 PM
Duration 60mins Washington, USA
Bleed experience in von Willebrand disease and validation of a Bleed and Medication Questionnaire
James P, Miesbach W, Castro Sanchez AY, Chang A, Czirok T, Lehle M, Ling G, Uguen M, Mahlangu J
Haematology | von Willebrand disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.